Navigation Links
Innocoll Receives 'Intends to Grant' Notices from the European Patent Office for Two European Patent Applications Related to Novel Wound Healing, Biosurgery and Drug Delivery Applications of its CollaRx(R) Technology
Date:11/28/2007

ASHBURN, Va., Nov. 28 /PRNewswire/ -- Innocoll, Inc. announced that its wholly-owned subsidiary, Syntacoll AG, has been notified that pursuant to Rule 51(4) EPC, the European Patent Office (EPO) intends to grant two of Innocoll's patent applications which are both based on its proprietary CollaRx technology; Patent No. 1259269 entitled "Agent for the Treatment of Wounds" and Patent No. 1265648 entitled "Novel Natural Polymer-Based Material with Improved Properties for Use in Human and Veterinary Medicine and the Method of Manufacture such".

The '269 patent is for an advanced wound care product comprised of a collagen or other natural polymer layer adhered to a synthetic polymer foam in a non-occlusive, ready-to-use format. The corresponding US Patent No. 6,855,860 entitled "Composite Dressings for Treatment of Wounds" is already granted and issued. In the preferred embodiment known as DermaSIL(TM), the collagen layer is a highly purified, fully biodegradable and resorbable type 1 collagen that retains the triple helical molecular structure of native collagen. This layer is placed in direct contact with the wound bed and is designed to stimulate the natural wound healing process and provide a matrix for the formation of granulation tissue. The synthetic polymer foam layer mechanically stabilizes the collagen layer, protects the wound, and provides permeability to air and moisture in maintaining an optimum wound healing environment. This layer is non-adhesive such that it can be easily removed upon dressing change without disrupting or disturbing the collagen layer, which remains in direct contact with the wound bed or else may already be fully biodegraded according to the residence time. The product is considered most suitable for the treatment of deep wounds that penetrate the middle and deepest layers of skin, or dermis. These deep wounds occur in second- or third-degree burns and in a variety of acute and/or chronic dermal wounds, such as diabetic ul
'/>"/>

SOURCE Innocoll, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine news :

1. Innocoll Agrees the Sale of its CollaRx(R) GENTAMICIN SURGICAL IMPLANT and European Sales and Marketing Infrastructure to EUSA Pharma
2. Lake Elsinore Family Caregiver Receives Free Power Wheelchair From The SCOOTER Store
3. DaVita Receives Civil Complaint
4. Ranbaxy Receives Tentative Approval to Manufacture and Market Galantamine Tablets on an Exclusive Basis
5. Watson Receives First FDA Approval for Manufacturing Product at Its Goa, India Facility
6. Edwards Lifesciences Receives CE Mark for Edwards SAPIEN Transcatheter Heart Valve
7. Mayo Clinic Multidisciplinary Simulation Center Receives Distinction as an ACS-Accredited Education Institute
8. PainCare Receives $14.4 Million in Cash From Completed Sale of South Florida Ambulatory Surgery Centers
9. UT Southwesterns obesity research receives $22 million NIH Roadmap grant
10. Temple Emergency Medicine receives $1.8M to find best MRSA treatment
11. Prime Therapeutics Receives TIPPS Certification
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Mach 7 Technologies Contracted by Singapore General Hospital to Provide State-of-the-Art Patient Image Management Technology 2Mach 7 Technologies Contracted by Singapore General Hospital to Provide State-of-the-Art Patient Image Management Technology 3AMP Receives $1.4 Million Grant From the Bill & Melinda Gates Foundation to Improve Advocacy for VACCINES and Immunization Systems in West Africa 2AMP Receives $1.4 Million Grant From the Bill & Melinda Gates Foundation to Improve Advocacy for VACCINES and Immunization Systems in West Africa 3Pharmacy Technician Employment Increasing Up to 32% By 2016 2Johns Hopkins researchers track down protein responsible for chronic rhinosinusitis with polyps 61897 1Johns Hopkins researchers track down protein responsible for chronic rhinosinusitis with polyps 61897 2Johns Hopkins researchers track down protein responsible for chronic rhinosinusitis with polyps 61897 3Dr Arun Gulani Listed in Forbes Magazine as One of The Leading Laser Eye Surgeons of the United States 61893 1Dr Arun Gulani Listed in Forbes Magazine as One of The Leading Laser Eye Surgeons of the United States 61893 2Missing Gene Tied to Bone Marrow Transplant Problems 61889 1